- Report
- February 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- January 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Report
- November 2022
- 291 Pages
Global
From €3063EUR$3,185USD£2,627GBP
€4375EUR$4,550USD£3,753GBP
- Report
- January 2023
- 154 Pages
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- January 2023
- 152 Pages
North America
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- January 2023
- 229 Pages
Middle East, Africa
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- January 2023
- 151 Pages
Europe
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- January 2023
- 183 Pages
Asia Pacific
From €2019EUR$2,100USD£1,732GBP
€2885EUR$3,000USD£2,475GBP
- Report
- May 2024
- 50 Pages
Global
From €2548EUR$2,650USD£2,186GBP
Atovaquone is an antibiotic used to treat a variety of infectious diseases, including malaria, toxoplasmosis, and pneumocystis pneumonia. It is a synthetic quinone compound that works by inhibiting the production of mitochondrial energy in the parasites that cause these diseases. Atovaquone is available in both oral and intravenous formulations, and is often used in combination with other drugs to increase its effectiveness. It is generally well-tolerated, with few side effects.
Atovaquone is a widely used drug in the treatment of infectious diseases, and is available from a number of pharmaceutical companies. Some of the major players in the market include GlaxoSmithKline, Merck, Pfizer, and Sanofi. Other companies that produce atovaquone include Bristol-Myers Squibb, Novartis, and Teva Pharmaceuticals. Show Less Read more